We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Test Could Predict Poor Outcomes in Lung Transplant Patients

By LabMedica International staff writers
Posted on 01 Jul 2025

Organ transplantation has dramatically transformed the management of patients suffering from organ failure. More...

Yet, the immune system of the recipient often perceives the transplanted organ as a foreign entity, triggering a defensive reaction that can result in severe complications. Bronchiolitis obliterans syndrome (BOS) is one such complication that commonly occurs after lung transplantation (LT) and hematopoietic stem cell transplantation (HSCT). BOS is marked by airway narrowing, fibrosis, and inflammation in the lungs, which leads to respiratory issues and poor graft survival. While immune responses and overlapping pathological and morphological traits of post-LT and post-HSCT BOS have been thoroughly investigated, the reasons why only some patients develop BOS and the genetic factors that might influence individual responses to the diseases and treatments remain unclear. A new study now shows that genetic testing can help identify patients at greater risk of developing complications after transplantation, allowing for preventive action to be taken earlier.

A research team at Pusan National University (Busan, South Korear) examined genetic variations in lung tissues obtained from patients who developed BOS after undergoing LT or HSCT. They utilized whole genome sequencing (WGS) on DNA extracted from lung tissue and blood samples from these patients, then assessed the data for genetic variants such as single-nucleotide polymorphisms (SNPs), insertions and deletions, and base substitutions. SNPs were found to be the most prevalent variant in both groups, with 731 identified in patients with post-LT BOS and 990 in those with post-HSCT BOS. The mutational burden was also higher in the post-HSCT BOS group compared to the post-LT BOS group. Mutations in the FCGBP and POM121 genes were found in both patient groups and were present in both the lung tissue and blood samples.

The FCGBP gene variant was chosen for further analysis due to its high prevalence among BOS patients and its suspected involvement in controlling mucosal immunity within the lungs. Significantly, individuals carrying the FCGBP variant had a greater likelihood of experiencing recurrent BOS, infections, and acute rejection events, which were associated with increased levels of donor-specific antibodies—factors that together raise the overall disease burden and mortality risk. According to findings published in The Journal of Heart and Lung Transplantation, screening for the FCGBP variant could enable clinicians to pinpoint high-risk individuals and initiate tailored immunosuppressive treatments at the right time. Additionally, gaining a clearer understanding of how FCGBP functions in immune regulation could support the development of new therapies aimed at protecting lung tissue and enhancing long-term outcomes for transplant recipients.

“By testing for this genetic variation before or shortly after the transplant, doctors can adjust the treatment plan, monitor patients more closely, and take preventive steps to reduce the risk of complications like BOS,” said Assistant Professor Yun Hak Kim, who led the research. “In the future, this gene variant could also be screened in routine blood tests to track transplant health and guide long-term care more effectively.”

Related Links:
Pusan National University


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.